JP6188728B2 - 核酸送達の区画化方法ならびにその組成物および使用 - Google Patents

核酸送達の区画化方法ならびにその組成物および使用 Download PDF

Info

Publication number
JP6188728B2
JP6188728B2 JP2014556699A JP2014556699A JP6188728B2 JP 6188728 B2 JP6188728 B2 JP 6188728B2 JP 2014556699 A JP2014556699 A JP 2014556699A JP 2014556699 A JP2014556699 A JP 2014556699A JP 6188728 B2 JP6188728 B2 JP 6188728B2
Authority
JP
Japan
Prior art keywords
nucleic acid
tissue
organ
treating
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014556699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015513528A (ja
JP2015513528A5 (enExample
Inventor
ホセ・グスタボ・カブレラ・アキノ
ブランカ・アンジェリカ・セグラ・パチェコ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Global Bio Therapeutics inc
Original Assignee
Global Bio Therapeutics inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Bio Therapeutics inc filed Critical Global Bio Therapeutics inc
Publication of JP2015513528A publication Critical patent/JP2015513528A/ja
Publication of JP2015513528A5 publication Critical patent/JP2015513528A5/ja
Application granted granted Critical
Publication of JP6188728B2 publication Critical patent/JP6188728B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1042—Alimentary tract
    • A61M2210/1071—Liver; Hepar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2014556699A 2012-02-07 2013-02-07 核酸送達の区画化方法ならびにその組成物および使用 Expired - Fee Related JP6188728B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261633287P 2012-02-07 2012-02-07
US61/633,287 2012-02-07
PCT/US2013/025234 WO2013119880A1 (en) 2012-02-07 2013-02-07 Compartmentalized method of nucleic acid delivery and compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017149223A Division JP6463421B2 (ja) 2012-02-07 2017-08-01 核酸送達の区画化方法ならびにその組成物および使用

Publications (3)

Publication Number Publication Date
JP2015513528A JP2015513528A (ja) 2015-05-14
JP2015513528A5 JP2015513528A5 (enExample) 2016-03-24
JP6188728B2 true JP6188728B2 (ja) 2017-08-30

Family

ID=47750057

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014556699A Expired - Fee Related JP6188728B2 (ja) 2012-02-07 2013-02-07 核酸送達の区画化方法ならびにその組成物および使用
JP2017149223A Expired - Fee Related JP6463421B2 (ja) 2012-02-07 2017-08-01 核酸送達の区画化方法ならびにその組成物および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017149223A Expired - Fee Related JP6463421B2 (ja) 2012-02-07 2017-08-01 核酸送達の区画化方法ならびにその組成物および使用

Country Status (15)

Country Link
US (2) US9821114B2 (enExample)
EP (2) EP2812012A1 (enExample)
JP (2) JP6188728B2 (enExample)
KR (1) KR102063195B1 (enExample)
CN (3) CN107982548A (enExample)
AU (1) AU2013216920B2 (enExample)
BR (1) BR112014019431A8 (enExample)
CA (1) CA2863964C (enExample)
EA (1) EA033803B1 (enExample)
HK (1) HK1204770A1 (enExample)
IL (1) IL233946B (enExample)
MX (1) MX367842B (enExample)
NZ (2) NZ715957A (enExample)
SG (3) SG10201604810UA (enExample)
WO (1) WO2013119880A1 (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
EP2812012A1 (en) 2012-02-07 2014-12-17 Global Bio Therapeutics USA, Inc. Compartmentalized method of nucleic acid delivery and compositions and uses thereof
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
WO2013166378A1 (en) 2012-05-03 2013-11-07 Indiana University Research And Technology Corporation Hydrodynamic methods for delivering fluids to kidney tissues and related materials and methods
HK1222093A1 (zh) * 2013-05-15 2017-06-23 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
ES2733911T3 (es) 2013-08-08 2019-12-03 Global Bio Therapeutics Inc Dispositivo de sujeción para procedimientos minimamente invasivos
EP3030171B1 (en) 2013-08-08 2017-11-01 Global Bio Therapeutics, Inc. Injection device for minimally invasive procedures
US10980985B2 (en) 2013-08-30 2021-04-20 Indiana University Research And Technology Corporation Hydrodynamic method and apparatus for delivering fluids to kidney tissues
US10219492B2 (en) * 2013-11-22 2019-03-05 The Board Of Regents Of The University Of Texas System Compounds and methods for altering RSV replication rate
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
KR102736149B1 (ko) * 2014-03-21 2024-11-28 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 뉴클레아제 없는 게놈 편집
JP6741590B2 (ja) * 2014-04-25 2020-08-19 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア コレステロールレベルを低下させるためのｌｄｌｒ変異体および組成物中でのそれらの使用
WO2015175539A1 (en) * 2014-05-12 2015-11-19 The Johns Hopkins University Engineering synthetic brain penetrating gene vectors
DE102015201100B4 (de) * 2015-01-22 2018-05-17 Friedrich-Alexander-Universität Erlangen-Nürnberg Antivirale Mittel
US10688285B2 (en) 2015-01-30 2020-06-23 The Regents Of The University Of California Spinal subpial gene delivery system
JP2018506530A (ja) * 2015-01-30 2018-03-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脊柱軟膜下遺伝子送達システム
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US11980663B2 (en) 2015-07-08 2024-05-14 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
WO2017106799A1 (en) 2015-12-17 2017-06-22 Modernatx, Inc. POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE
IL279520B2 (en) 2016-01-15 2023-03-01 American Gene Tech Int Inc Methods and preparations for the activation of gamma-delta t cells
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
US20190038717A1 (en) * 2016-02-04 2019-02-07 Slbigen Inc. Mesenchymal stem cell expressing hepatocyte growth factor, and use thereof
WO2017139065A1 (en) 2016-02-08 2017-08-17 American Gene Technologies International Inc. Hiv vaccination and immunotherapy
EP3426777B1 (en) 2016-03-09 2022-02-16 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
AU2017241534A1 (en) 2016-03-28 2018-10-04 The Regents Of The University Of California Method and composition for treating neuronal hyper-excitability
SG11201808176TA (en) 2016-04-15 2018-10-30 The Trustees Of The Univ Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
CA3024507A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease
WO2017201347A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2017213697A1 (en) 2016-06-08 2017-12-14 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
US11045557B2 (en) 2016-06-09 2021-06-29 Queen's University At Kingston Methods and gene therapy constructs for treating GM2 gangliosidoses
EP3481418A4 (en) 2016-07-08 2020-03-11 American Gene Technologies International Inc. PRE-IMMUNIZATION AND IMMUNOTHERAPY OF HIV
EP3487507A4 (en) 2016-07-21 2020-04-08 American Gene Technologies International, Inc. VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE
KR101671361B1 (ko) * 2016-08-08 2016-11-01 에스씨엠생명과학 주식회사 TYMP(thymidine phosphorylase) 단백질을 유효성분으로 포함하는 탈모 예방 또는 치료용 약학적 조성물
US11266344B2 (en) 2016-09-21 2022-03-08 Samsung Electronics Co., Ltd. Method for measuring skin condition and electronic device therefor
ES2859661T3 (es) * 2016-09-30 2021-10-04 Esteve Pharmaceuticals Sa Vectores de virus adenoasociados para el tratamiento de mucopolisacaridosis
KR20190127655A (ko) 2016-10-19 2019-11-13 프로디자인 소닉스, 인크. 음향학에 의한 친화성 세포 추출
EP3607072A4 (en) 2017-04-03 2021-01-06 American Gene Technologies International Inc. COMPOSITIONS AND METHODS OF TREATMENT OF PHENYLCETONURISM
WO2019014652A1 (en) * 2017-07-13 2019-01-17 Memphis Meats, Inc. COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF CELL CULTURES USED IN FOOD PRODUCTION
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
WO2019039863A2 (ko) * 2017-08-23 2019-02-28 주식회사 압타머사이언스 대리 바이러스를 이용한 압타머 제조 방법
KR102640462B1 (ko) 2017-09-08 2024-02-23 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 신경병증성 통증의 치료를 위한 방법 및 조성물
CA3076036A1 (en) 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
KR20200057766A (ko) * 2017-10-02 2020-05-26 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 페닐케톤뇨증을 치료하기 위한 프로모터 및 인핸서 조합을 포함하는 벡터
CN119242711A (zh) 2017-10-16 2025-01-03 沃雅戈治疗公司 肌萎缩性侧索硬化症（als）的治疗
MA50803A (fr) 2017-11-22 2020-09-30 Modernatx Inc Polynucléotides codant pour l'ornithine transcarbamylase pour le traitement de troubles du cycle de l'urée
EP3725092A4 (en) 2017-12-14 2021-09-22 FloDesign Sonics, Inc. DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER
KR102112476B1 (ko) 2017-12-29 2020-05-19 주식회사 헬릭스미스 하이브리드 HGF 유전자가 도입된 AAV(Adeno-Associated Virus) 벡터
CN111936617A (zh) * 2018-03-16 2020-11-13 益缪索夫特公司 经遗传工程化以分泌卵泡抑素的b细胞以及使用所述b细胞来治疗卵泡抑素相关的疾病、病况、病症及增强肌肉生长和力量的方法
CN108576402A (zh) * 2018-03-22 2018-09-28 昆明三正生物科技（集团）有限公司 一种乳仔猪专用酶生产方法
SG11202009895TA (en) 2018-04-27 2020-11-27 Krystal Biotech Inc Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
US20210254103A1 (en) * 2018-07-02 2021-08-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
CA3106590A1 (en) 2018-07-16 2020-01-23 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
WO2020047472A1 (en) * 2018-08-30 2020-03-05 Research Institute At Nationwide Children's Hospital Gene therapy for the treatment of galactosemia
AU2019344006B2 (en) * 2018-09-21 2025-11-27 University Of Connecticut Compositions and methods to restore paternal UBE3A gene expression in human Angelman Syndrome
CN109504709B (zh) * 2018-11-28 2020-07-24 上海安民生物技术有限公司 白蛋白启动子驱动的白蛋白表达载体
EP3908198B1 (en) 2019-01-10 2024-12-11 The Regents of the University of California Subpial delivery system
WO2020144295A1 (en) * 2019-01-10 2020-07-16 Biontech Rna Pharmaceuticals Gmbh Localized administration of rna molecules for therapy
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
CN110272810A (zh) * 2019-07-01 2019-09-24 广州世赛生物科技有限公司 外源物质递送至真核细胞内的装置和方法及其应用
EP4073106A2 (en) * 2019-12-12 2022-10-19 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
USD963164S1 (en) 2020-01-09 2022-09-06 The Regents Of The University Of California Surgical needle
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
WO2022081776A1 (en) 2020-10-13 2022-04-21 Kriya Therapeutics, Inc. Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
WO2022213353A1 (en) * 2021-04-09 2022-10-13 Peking University Sirna, medical compositions, and methods for treating diabetes using the same
CN115074344B (zh) * 2022-06-24 2023-09-19 徐州医科大学 一种多层次严格调控自杀蛋白rCas8活性系统及其应用
TW202444398A (zh) * 2023-01-09 2024-11-16 美商拜奧馬林製藥公司 表觀遺傳修飾劑改善aav基因療法之耐久性
WO2025038011A1 (en) * 2023-08-11 2025-02-20 Joint Stock Company «Biocad» Modified sequence of adenovirus e2a gene for producing vectors based on adeno-associated viruses (aav) (variants)
WO2025049818A1 (en) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Tnfr1 antagonists lacking agonist activity and uses thereof

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US567048A (en) 1896-09-01 Wedge for filling and tightening wood joints
US3667471A (en) 1969-08-15 1972-06-06 Us Army Surgical clamp
US4652525A (en) 1978-04-19 1987-03-24 The Regents Of The University Of California Recombinant bacterial plasmids containing the coding sequences of insulin genes
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4431740A (en) 1979-09-12 1984-02-14 The Regents Of The University Of California DNA Transfer vector and transformed microorganism containing human proinsulin and pre-proinsulin genes
US4328803B1 (en) 1980-10-20 1994-01-11 Opthalmic Systems, Inc. Opthalmological procedures
US4738927A (en) 1982-03-31 1988-04-19 Ajinomoto Co. Inc. Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4517295A (en) 1983-02-18 1985-05-14 Diagnostic, Inc. Hyaluronic acid from bacterial culture
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US6696420B1 (en) 1984-11-20 2004-02-24 Institut Pasteur Adenoviral vector with a deletion in the E1A coding region expressing a hetorologous protein
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
EP0275598B1 (en) 1986-12-16 1998-01-07 Gist-Brocades N.V. Molecular cloning and expression of human IL-3
OA09736A (en) 1987-02-18 1993-11-30 Schering Biotech Corp "Human interleukin-3 and muteins thereof".
US5282851A (en) 1987-07-07 1994-02-01 Jacob Labarre Jean Intraocular prostheses
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5229127A (en) 1989-03-03 1993-07-20 Mckinzie James W Rapid miosis with control of intraocular pressure using a mixture of a cetylcholine and carbachol derivatives
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5292362A (en) 1990-07-27 1994-03-08 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
EP0561965A4 (en) 1990-12-03 1997-03-19 Us Health Enhancement of musculature in animals
US5203786A (en) 1991-06-19 1993-04-20 Thomas Jefferson University Hepatic resection clamp
JPH07503372A (ja) 1992-01-23 1995-04-13 バイカル・インコーポレイテッド 生体外遺伝子導入
US5273056A (en) 1992-06-12 1993-12-28 Alcon Laboratories, Inc. Use of combinations of viscoelastics during surgery
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
ATE322547T1 (de) 1993-06-10 2006-04-15 Genetic Therapy Inc Adenovirale vektoren für die behandlung der hämophilie
US5919676A (en) 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
US5543328A (en) 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
WO1995026411A2 (en) 1994-03-25 1995-10-05 The Uab Research Foundation Composition and methods for creating syngeneic recombinant virus-producing cells
WO1995029993A1 (en) 1994-04-28 1995-11-09 The University Of Michigan Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
JPH10505502A (ja) 1994-09-12 1998-06-02 シェーリング アクチェンゲゼルシャフト 修飾されたコラーゲン誘導血小板凝集阻害剤パリジピンの製法
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5869230A (en) 1995-03-30 1999-02-09 Beth Israel Hospital Association Gene transfer into the kidney
PT833934E (pt) 1995-06-15 2005-02-28 Crucell Holland Bv Sistemas de empacotamento para adenovivrus recombinente humano destinados a terapia genetica
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US5622856A (en) 1995-08-03 1997-04-22 Avigen High efficiency helper system for AAV vector production
US20020001574A1 (en) 1995-12-13 2002-01-03 Jon A. Woiff Process of delivering a polynucleotide to a muscle cell via the vascular system
US20010009904A1 (en) 1997-12-30 2001-07-26 Jon A. Wolff Process of delivering a polynucleotide to a cell via the vascular system
DE19600328C1 (de) 1996-01-08 1997-02-13 Zimmermann Jos Gmbh & Co Kg Tuftingnadeln für ein Nadelmodul
US6121247A (en) * 1996-03-29 2000-09-19 The Johns Hopkins University Therapy for allergic diseases
DE19620687A1 (de) * 1996-05-22 1997-11-27 Centeon Pharma Gmbh Neuer adenoviraler Vektor für den Transfer humaner Gene in vivo
US5785689A (en) 1996-07-18 1998-07-28 Act Medical, Inc. Endoscopic catheter sheath position control
WO1998006437A2 (en) 1996-08-13 1998-02-19 Chiron Corporation Compositions and methods for polynucleotide delivery
US5704908A (en) 1996-10-10 1998-01-06 Genetronics, Inc. Electroporation and iontophoresis catheter with porous balloon
US20080305999A1 (en) 1996-11-01 2008-12-11 John Francis Martin Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6183444B1 (en) 1998-05-16 2001-02-06 Microheart, Inc. Drug delivery module
ES2177240T3 (es) 1998-01-27 2002-12-01 Hemebiotech As Tratamiento para la porfiria aguda intermitente (pai) y otras enfermedades porfiricas.
US5997509A (en) 1998-03-06 1999-12-07 Cornell Research Foundation, Inc. Minimally invasive gene therapy delivery device and method
JP2002536029A (ja) 1998-05-21 2002-10-29 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ 治療物質の圧力介在型選択的送達のための方法およびカニューレ
WO1999064615A1 (en) 1998-06-08 1999-12-16 Valentis, Inc. Formulations for electroporation
WO2000009675A1 (en) 1998-08-14 2000-02-24 Aventis Pharmaceuticals Products Inc. Adenovirus formulations for gene therapy
JP2002528128A (ja) 1998-11-02 2002-09-03 ユニバーシティ オブ サスカチュワン 組換えアデノウイルスベクターの増殖のためのアデノウイルス必須機能を発現するウシ細胞
GB9824437D0 (en) 1998-11-06 1999-01-06 Ylo Herttuala Seppo Gene therapy
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
AU5799200A (en) 1999-06-24 2001-01-31 Academic Hospital At The University Of Amsterdam Lpl variant therapeutics
JP2003516124A (ja) 1999-10-15 2003-05-13 ユニバーシティー オブ マサチューセッツ 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子
US7329728B1 (en) 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
US6218186B1 (en) 1999-11-12 2001-04-17 Trustees Of The University Of Pennsylvania HIV-MSCV hybrid viral vector for gene transfer
EP1309726B2 (en) 2000-03-30 2018-10-03 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
EP1290161B1 (en) 2000-05-30 2011-06-22 Johnson & Johnson Research Pty Limited METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi
GB0013105D0 (en) * 2000-05-30 2000-07-19 Univ Bristol Therapeutic compounds
US7011972B2 (en) 2000-07-18 2006-03-14 The Scripps Research Institute Fusion polypeptide comprising two ligand binding domains
US6821264B1 (en) 2000-11-27 2004-11-23 Gautam Khurana Gene delivery device and gene delivery method
IL152420A0 (en) 2001-02-23 2003-05-29 Novartis Ag Novel oncolytic adenoviral vectors
US20040009151A1 (en) 2002-04-04 2004-01-15 Kay Mark A. Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
WO2003104413A2 (en) 2002-06-05 2003-12-18 University Of Florida Production of pseudotyped recombinant aav virions
AU2003256280A1 (en) 2002-06-24 2004-01-06 Genzyme Corporation Methods of delivering gene therapy agents
JP5051679B2 (ja) 2003-08-29 2012-10-17 日本パーカライジング株式会社 アルミニウムまたはアルミニウム合金製ｄｉ缶のアルカリ洗浄方法
WO2005049094A1 (en) 2003-11-13 2005-06-02 Advantagene, Inc. A mixed complementary viral vector for gene therapy
WO2005060746A1 (en) 2003-12-11 2005-07-07 Mirus Corporation Delivery of viral vectors to extravascular parenchymal cells
US20050129660A1 (en) 2003-12-11 2005-06-16 Hagstrom James E. Process of delivering a virally encapsulated polynucleotide or viral vector to a parenchymal cell via the vascular system
GB0406728D0 (en) 2004-03-25 2004-04-28 Hydrodynamic Gene Delivery Ltd Gene therapy
US7645285B2 (en) 2004-05-26 2010-01-12 Idx Medical, Ltd Apparatus and methods for occluding a hollow anatomical structure
CN101068575A (zh) 2004-12-01 2007-11-07 建新公司 向肝脏定向递送遗传物质的方法
SG158133A1 (en) 2004-12-31 2010-01-29 Sonne Holm Method for reversing multiple resistance in animal cells
US8092464B2 (en) 2005-04-30 2012-01-10 Warsaw Orthopedic, Inc. Syringe devices and methods useful for delivering osteogenic material
EP1928504B1 (en) 2005-08-19 2013-04-24 University of Technology, Sydney Liver-directed gene therapy
WO2008108890A2 (en) * 2006-10-18 2008-09-12 University Of Rochester Conditionally replicating viruses for cancer therapy
WO2008049246A2 (de) 2006-10-25 2008-05-02 Pi-Design Ag Elektrischer milchschäumer
US20080119880A1 (en) 2006-11-16 2008-05-22 Chu David Z J Laparoscopic surgical clamp
WO2008122048A2 (en) * 2007-04-02 2008-10-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Removal of contrast agents from blood
EP2195439B1 (en) 2007-09-19 2013-06-19 UniQure IP B.V. Use of aav replication machinery for improved protein production
EP2068294A1 (en) 2007-12-03 2009-06-10 Endosim Limited Laparoscopic training apparatus
US20100234862A1 (en) 2007-12-06 2010-09-16 Manoj Patel Surgical clamp and method of clamping an organ
ES2507540T3 (es) 2008-09-29 2014-10-15 Uniqure Ip B.V. Terapia génica de porfobilinógeno deaminasa
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US20110305772A1 (en) 2009-02-26 2011-12-15 The Johns Hopkins University Compositions and methods for ex vivo hepatic nucleic acid delivery
EP2432497A1 (en) 2009-05-18 2012-03-28 Amsterdam Molecular Therapeutics (AMT) IP B.V. Use of lipoprotein lipase (lpl) in therapy
EP2812012A1 (en) 2012-02-07 2014-12-17 Global Bio Therapeutics USA, Inc. Compartmentalized method of nucleic acid delivery and compositions and uses thereof
EP3030171B1 (en) 2013-08-08 2017-11-01 Global Bio Therapeutics, Inc. Injection device for minimally invasive procedures
ES2733911T3 (es) 2013-08-08 2019-12-03 Global Bio Therapeutics Inc Dispositivo de sujeción para procedimientos minimamente invasivos

Also Published As

Publication number Publication date
SG10201609345QA (en) 2017-01-27
IL233946B (en) 2019-07-31
WO2013119880A1 (en) 2013-08-15
NZ627992A (en) 2017-02-24
IL233946A0 (en) 2014-09-30
HK1204770A1 (en) 2015-12-04
JP2015513528A (ja) 2015-05-14
US20180055997A1 (en) 2018-03-01
EP3970734A3 (en) 2022-04-20
BR112014019431A8 (pt) 2017-07-11
CA2863964C (en) 2021-10-26
NZ715957A (en) 2017-08-25
EP3970734A2 (en) 2022-03-23
EA201400871A1 (ru) 2015-04-30
CN104428009A (zh) 2015-03-18
CA2863964A1 (en) 2013-08-15
AU2013216920B2 (en) 2016-09-22
SG11201404741VA (en) 2014-09-26
JP6463421B2 (ja) 2019-02-06
SG10201604810UA (en) 2016-08-30
EA033803B1 (ru) 2019-11-27
US9821114B2 (en) 2017-11-21
US20130211380A1 (en) 2013-08-15
EP2812012A1 (en) 2014-12-17
JP2017197579A (ja) 2017-11-02
KR20140146062A (ko) 2014-12-24
MX367842B (es) 2019-09-09
CN107982548A (zh) 2018-05-04
WO2013119880A9 (en) 2013-10-03
CN110917362A (zh) 2020-03-27
KR102063195B1 (ko) 2020-01-07
AU2013216920A1 (en) 2014-08-28
MX2014009480A (es) 2015-04-13
BR112014019431A2 (enExample) 2017-06-20

Similar Documents

Publication Publication Date Title
JP6463421B2 (ja) 核酸送達の区画化方法ならびにその組成物および使用
JP6591585B2 (ja) 低侵襲処置用クランプデバイスおよびその使用
KR20150005521A (ko) 세포, 기관 및 조직으로의 유전자 전이를 위한 ａａｖ 벡터 조성물 및 방법
JP7710265B2 (ja) 酸化ストレス抵抗性を有する間葉系幹細胞、この製造方法および用途
Wal et al. Current Landscape of Gene Therapy for the Treatment of Cardiovascular Disorders
US20240043796A1 (en) Cell sheet for gene delivery
US6132989A (en) Methods and compositions for enhanced stability of non-adenoviral DNA
TW202521698A (zh) 用於目標基因的表現匣及其應用
HK1225258A1 (en) Clamp device for minimally invasive procedures
Papanikolaou et al. Novel Therapies for Heart Failure: The Gene and Cell Methods
Panakanti Therapeutic gene delivery to human pancreatic islets for treatment of diabetes and the effect of TFO on liver fibrosis induced by bile duct ligation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160202

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20160331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160331

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170531

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170704

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170801

R150 Certificate of patent or registration of utility model

Ref document number: 6188728

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees